Robert received his PhD in Biochemistry from the Leiden University Medical Center where he studied oncogenic cell transformation in the lab of Prof. van de Eb. He subsequently moved to Stanford University (USA) to pursue his post-doctoral career on neural stem cells. Upon his return to the Netherlands, he joined the group of Prof. Hans Clevers at the Hubrecht Institute where he was involved in the development of the breakthrough “Organoid Technology” that allows the expansion of adult stem cells and the development of “mini-organs in a dish”. Rob is currently CEO of HUB, which was founded to further develop and refine the Organoid Technology.
Novel Organoid Models to Develop Drug Treatment Strategies
Wednesday, 9 September 2020 at 10:00
Add to Calendar ▼2020-09-09 10:00:002020-09-09 11:00:00Europe/LondonNovel Organoid Models to Develop Drug Treatment StrategiesPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Organoids such as IPSC derived brain organoids (Lancaster et al Nature
2013) or our adults epithelial stem cell derived organoids (Sato et al.,
Nature 2009, 2011) are proving to be a major breakthrough in
preclinical models. The new patient like models are fundamental change
in the way drug discovery and development can be performed. The
development of the HUB Organoids started in the lab of Hans Clevers with
the discovery of the identity of adult stem cells in human epithelial
tissues such as intestine and liver (Barker et al., Nature 2007; Huch et
al., Nature 2013). With the identification of these stem cells, we were
able to develop a culture system that allowed for the virtually
unlimited, genetically and phenotypically stable expansion of the
epithelial cells from animals including humans, both from healthy and
diseased tissue (Sato et al., Nature 2009, 2011; Gastroenterology 2011;
Huch et al., Nature 2013, Cell 2015; Boj et al., Cell 2015).
We
have now generated HUB organoid models from most epithelial organs.
Recently, we and others have demonstrated that the in vitro response of
organoids correlates with the clinical outcome of the patient from which
the organoid was derived (Dekkers et al., Sci Trans Med 2016; Sachs et
al., Cell 2018; Vlachogiannis et al., Science 2018). In addition, we
have developed a coculture system using HUB Organoids and the immune
system to study this interaction and drugs that target the role of the
immune system in cancer and other diseases.
We have recently
developed new models to study intestinal and lung barrier function and
transport of the epithelium of these organs. These experiments show how
organoids can be used to study mechanism that underly barrier function
disruption in IBD or COPD. Furthermore, we have developed new models to
study the interaction between immune system and epithelium. The
combination of the new coculture models and assay development to study
the epithelium allows us new insights into disease mechanisms and drug
treatment strategies.
Add to Calendar ▼2020-09-09 00:00:002020-09-10 00:00:00Europe/LondonPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020Point-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2020-09-09 10:00:002020-09-09 11:00:00Europe/LondonNovel Organoid Models to Develop Drug Treatment StrategiesPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
